AbbVie (ABBV) FCF Margin Growth (1y) (2013 - 2026)
Powered by 
Analysis
AbbVie (ABBV) FCF Margin Growth (1y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | 1,688.00 |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | -1,334.00 |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | 1,096.00 |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | -672.00 |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | 1,020.00 |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | 1,090.00 |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | - |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | 2,747.00 |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | 1,003.00 |
| 10 | Neurocrine Biosciences | 15.82 Bn | 15.43 Bn | 935.80 Mn | 39.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,334.00 |
| Mar 31, 2026 | 1,326.00 |
| Dec 31, 2025 | -1,532.00 |
| Sep 30, 2025 | 616.00 |
| Jun 30, 2025 | 1,763.00 |
| Mar 31, 2025 | -2,076.00 |
| Dec 31, 2024 | 1,294.00 |
| Sep 30, 2024 | -1,686.00 |
| Jun 30, 2024 | -3,025.00 |
| Mar 31, 2024 | -162.00 |
| Dec 31, 2023 | -1,591.00 |
| Sep 30, 2023 | 268.00 |
| Jun 30, 2023 | 1,095.00 |
| Mar 31, 2023 | -219.00 |
| Dec 31, 2022 | 1,488.00 |
| Sep 30, 2022 | -369.00 |
| Jun 30, 2022 | -29.00 |
| Mar 31, 2022 | -98.00 |
| Dec 31, 2021 | -18.00 |
| Sep 30, 2021 | 1,031.00 |